19.72
-0.23(-1.15%)
Currency In USD
| Previous Close | 19.95 |
| Open | 20.05 |
| Day High | 20.76 |
| Day Low | 19.52 |
| 52-Week High | 32.27 |
| 52-Week Low | 13.37 |
| Volume | 133,529 |
| Average Volume | 344,346 |
| Market Cap | 633.52M |
| PE | -7.73 |
| EPS | -2.55 |
| Moving Average 50 Days | 20.11 |
| Moving Average 200 Days | 24.35 |
| Change | -0.23 |
If you invested $1000 in Dianthus Therapeutics, Inc. (DNTH) since IPO date, it would be worth $85.87 as of May 07, 2025 at a share price of $19.95. Whereas If you bought $1000 worth of Dianthus Therapeutics, Inc. (DNTH) shares 5 years ago, it would be worth $128.02 as of May 07, 2025 at a share price of $19.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
GlobeNewswire Inc.
May 05, 2025 11:00 AM GMT
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-clas
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
GlobeNewswire Inc.
Apr 29, 2025 11:00 AM GMT
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoim
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
GlobeNewswire Inc.
Mar 05, 2025 12:00 PM GMT
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first